Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Resistance to endocrine treatment occurs in ~30% of ER(+) breast cancer patients resulting in ~40,000 deaths/year in the USA. Preclinical studies strongly implicate activation of growth factor receptor, HER2 in endocrine treatment resistance. However, clinical trials of pan-HER inhibitors in ER(+)/H...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Nat Commun
Auteurs principaux: Punturi, Nindo B., Seker, Sinem, Devarakonda, Vaishnavi, Mazumder, Aloran, Kalra, Rashi, Chen, Ching Hui, Li, Shunqiang, Primeau, Tina, Ellis, Matthew J., Kavuri, Shyam M., Haricharan, Svasti
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8134423/
https://ncbi.nlm.nih.gov/pubmed/34011995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-23271-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires